

©Royal Society of Chemistry

Electronic Supporting Information

Host-guest complexations of local anaesthetics by cucurbit[7]uril in aqueous solution


Ian W. Wyman and Donal H. Macartney\*

Department of Chemistry, Queen's University, 90 Bader Lane, Kingston, Ontario K7L 3N6, Canada.


Fax: +1 613 533 6669; Tel: +1 613 533 2617; E-mail: donal@chem.queensu.ca

Contents	Page
<b>Figure S1.</b> $^1\text{H}$ NMR titration of procaine ( $1.02 \text{ mmol dm}^{-3}$ ) with CB[7] in $\text{D}_2\text{O}$ . (a) 0.0 equiv, (b) 0.30 equiv, (c) 0.57 equiv, (d) 0.96 equiv, and (e) 1.18 equiv of CB[7].	S3
<b>Figure S2.</b> $^1\text{H}$ NMR chemical shift titration of procaine ( $1.02 \text{ mmol dm}^{-3}$ ) with CB[7] in $\text{D}_2\text{O}$ . (●) $\text{H}\alpha$ and (○) $\text{H}\beta'$ .	S4
<b>Figure S3.</b> $^1\text{H}$ NMR titration of procaine ( $1.02 \text{ mmol dm}^{-3}$ ) with CB[7] in $\text{D}_2\text{O}/0.10 \text{ mol dm}^{-3}$ DCl. (a) 0.0 equiv, (b) 0.33 equiv, (c) 0.92 equiv, and (d) 1.28 equiv of CB[7].	S5
<b>Figure S4.</b> $^1\text{H}$ NMR chemical shift titration of procaine ( $1.02 \text{ mmol dm}^{-3}$ ) with CB[7] in $\text{D}_2\text{O}$ containing 0.10 M DCl. (●) $\text{H}_2$ , (○) $\text{H}_3$ , and (▼) $\text{H}\beta'$ .	S6
<b>Figure S5.</b> $^1\text{H}$ NMR titration of tetracaine ( $1.33 \text{ mmol dm}^{-3}$ ) with CB[7] in $\text{D}_2\text{O}$ . (a) 0.0 equiv, (b) 0.40 equiv, (c) 0.84 equiv, and (d) 1.29 equiv of CB[7].	S7
<b>Figure S6.</b> $^1\text{H}$ NMR chemical shift titration of tetracaine ( $1.33 \text{ mmol dm}^{-3}$ ) by CB[7] in $\text{D}_2\text{O}$ . (●) $\text{H}4'$ , (○) $\text{H}_2$ , (▼) $\text{H}_3$ , (▽) $\text{H}\alpha'$ , (■) $\text{H}\beta$ , (□) $\text{H}3'$ , and (◆) $\text{H}2'$ .	S8
<b>Figure S7.</b> $^1\text{H}$ NMR titration of tetracaine ( $1.03 \text{ mol dm}^{-3}$ ) with CB[7] in $\text{D}_2\text{O}$ containing $0.10 \text{ mol dm}^{-3}$ DCl. (a) 0.0 equiv, (b) 0.29 equiv, (c) 0.49 equiv, (d) 0.78 equiv, and (e) 1.18 equiv of CB[7].	S9
<b>Figure S8.</b> $^1\text{H}$ NMR chemical shift titration of tetracaine ( $1.33 \text{ mmol dm}^{-3}$ ) by CB[7] in $\text{D}_2\text{O}$ containing $0.10 \text{ mol dm}^{-3}$ DCl. (●) $\text{H}4'$ , (○) $\text{H}_2$ , (▼) $\text{H}\alpha$ , (▽) $\text{H}1'$ , (■) $\text{H}\beta$ , (□) $\text{H}3'$ , and (◆) $\text{H}2'$ .	S10
<b>Figure S9.</b> $^1\text{H}$ NMR titration of dibucaine ( $1.01 \text{ mmol dm}^{-3}$ ) with CB[7] in $\text{D}_2\text{O}$ . (a) 0.0 equiv, (b) 0.21 equiv, (c) 0.44 equiv, (d) 0.68 equiv and (e) 1.37 equiv of CB[7].	S11
<b>Figure S10.</b> $^1\text{H}$ NMR chemical shift titration of dibucaine ( $1.01 \text{ mmol dm}^{-3}$ ) by CB[7] in $\text{D}_2\text{O}$ . (●) $\text{H}\beta'$ , (○) $\text{H}\alpha'$ , (▼) $\text{H}\alpha$ , (▽) $\text{H}_4$ , and (■) $\text{H}_8$ .	S12
<b>Figure S11.</b> $^1\text{H}$ NMR titration of dibucaine ( $1.02 \text{ mmol dm}^{-3}$ ) with CB[7] in $\text{D}_2\text{O}$	


- containing  $0.10 \text{ mol dm}^{-3}$  DCl. (a) 0.0 equiv, (b) 0.31 equiv, (c) 0.78 equiv, and (d) 1.24 equiv of CB[7]. S13
- Figure S12.**  $^1\text{H}$  NMR chemical shift titration of dibucaine ( $1.02 \text{ mmol dm}^{-3}$ ) by CB[7] in  $\text{D}_2\text{O}$  containing  $0.10 \text{ mol dm}^{-3}$  DCl. (●)  $\text{H}'$ , (○)  $\text{H}_2$ , (▼)  $\text{H}\alpha$ , (▽)  $\text{H}1'$ , (■)  $\text{H}\beta$ , (□)  $\text{H}3'$ , and (◆)  $\text{H}2'$ . S14
- Figure S13.**  $^1\text{H}$  NMR spectra of prilocaine ( $1.27 \text{ mmol dm}^{-3}$ ) in  $\text{D}_2\text{O}$ . (a) 0.0 equiv, (b) 0.31 equiv, (c) 0.68 equiv, and (d) 1.80 equiv of CB[7]. S15
- Figure S14.**  $^1\text{H}$  NMR chemical shift titration of prilocaine ( $1.27 \text{ mmol dm}^{-3}$ ) with CB[7] in  $\text{D}_2\text{O}$ . (●)  $\text{H}\alpha$ . S16
- Figure S15.**  $^1\text{H}$  NMR spectra of procainamide ( $1.10 \text{ mmol dm}^{-3}$ ) with (a) 0.0 equiv, (b) 0.39 equiv, (c) 0.72 equiv, and (d) 1.88 equiv of CB[7] in  $\text{D}_2\text{O}$ . S17
- Figure S16.**  $^1\text{H}$  NMR chemical shift titration of procainamide (1.01 mM) with CB[7] in  $\text{D}_2\text{O}$ . (●)  $\text{H}\beta'$ , (○)  $\text{H}\alpha'$ , and (▼)  $\text{H}_2$ . S18
- Figure S17.**  $^1\text{H}$  NMR spectra of procainamide ( $1.01 \text{ mmol dm}^{-3}$ ) with (a) 0.0 equiv, (b) 0.39 equiv, (c) 0.79 equiv, and (d) 1.53 equiv of CB[7] in  $\text{D}_2\text{O}$  in the presence of  $0.10 \text{ mol dm}^{-3}$  DCl. S19
- Figure S18.**  $^1\text{H}$  NMR chemical shift titration of procainamide (1.01 mM) with CB[7] in  $\text{D}_2\text{O}$  containing  $0.10 \text{ mol dm}^{-3}$  DCl. (●)  $\text{H}_2$ , (○)  $\text{H}_3$ , (▼)  $\text{H}\beta'$ , and (▽)  $\text{H}\alpha'$ . S20
- Figure S19.** UV titration of procaine ( $50 \text{ }\mu\text{mol dm}^{-3}$ ) with CB[7] in  $\text{H}_2\text{O}$ . Inset: Dependence of absorbance at 290 nm on the concentration of CB[7]. S21
- Table S1.** Mass spectral data for the 1:1 and 2:1 CB[7] host-guest complexes with the local anaesthetic guests in water. S22




**Figure S1.** <sup>1</sup>H NMR titration of procaine (1.02 mmol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O. (a) 0.0 equiv, (b) 0.30 equiv, (c) 0.57 equiv, (d) 0.96 equiv, and (e) 1.18 equiv of CB[7].



**Figure S2.** <sup>1</sup>H NMR chemical shift titration of procaine (1.02 mmol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O. (•) H $\alpha$  and (○) H $\beta'$ .




**Figure S3.** <sup>1</sup>H NMR titration of procaine (1.02 mmol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O/0.10 mol dm<sup>-3</sup> DCl. (a) 0.0 equiv, (b) 0.33 equiv, (c) 0.92 equiv, and (d) 1.28 equiv of CB[7].




**Figure S4.** <sup>1</sup>H NMR chemical shift titration of procaine (1.02 mmol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O containing 0.10 M DCl. (•) H<sub>2</sub>, (○) H<sub>3</sub>, and (▼) Hβ'.




**Figure S5.** <sup>1</sup>H NMR titration of tetracaine (1.33 mmol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O. (a) 0.0 equiv, (b) 0.40 equiv, (c) 0.84 equiv, and (d) 1.29 equiv of CB[7].




**Figure S6.** <sup>1</sup>H NMR chemical shift titration of tetracaine (1.33 mmol dm<sup>-3</sup>) by CB[7] in D<sub>2</sub>O. (●) H4', (○) H2, (▼) H3, (▽) Hα', (■) Hβ, (□) H3', and (◆) H2'.




**Figure S7.** <sup>1</sup>H NMR titration of tetracaine (1.03 mol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O containing 0.10 mol dm<sup>-3</sup> DCl. (a) 0.0 equiv, (b) 0.29 equiv, (c) 0.49 equiv, (d) 0.78 equiv, and (e) 1.18 equiv of CB[7].




**Figure S8.** <sup>1</sup>H NMR chemical shift titration of tetracaine (1.33 mmol dm<sup>-3</sup>) by CB[7] in D<sub>2</sub>O containing 0.10 mol dm<sup>-3</sup> DCl. (●) H4', (○) H2, (▼) Hα, (▽) H1', (■) Hβ, (□) H3', and (◆) H2'.




**Figure S9.** <sup>1</sup>H NMR titration of dibucaine (1.01 mmol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O. (a) 0.0 equiv, (b) 0.21 equiv, (c) 0.44 equiv, (d) 0.68 equiv and (e) 1.37 equiv of CB[7].




**Figure S10.** <sup>1</sup>H NMR chemical shift titration of dibucaine (1.01 mmol dm<sup>-3</sup>) by CB[7] in D<sub>2</sub>O. (●) Hb', (○) Hα', (▼) Hα, (▽) H4, and (■) H8.




**Figure S11.** <sup>1</sup>H NMR titration of dibucaine (1.02 mmol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O containing 0.10 mol dm<sup>-3</sup> DCl. (a) 0.0 equiv, (b) 0.31 equiv, (c) 0.78 equiv, and (d) 1.24 equiv of CB[7].




**Figure S12.** <sup>1</sup>H NMR chemical shift titration of dibucaine (1.02 mmol dm<sup>-3</sup>) by CB[7] in D<sub>2</sub>O containing 0.10 mol dm<sup>-3</sup> DCl. (●) H', (○) H<sub>2</sub>, (▼) H<sub>α</sub>, (▽) H<sub>1</sub>', (■) H<sub>β</sub>, (□) H<sub>3</sub>', and (◆) H<sub>2</sub>'.




**Figure S13.** <sup>1</sup>H NMR spectra of prilocaine (1.27 mmol dm<sup>-3</sup>) in D<sub>2</sub>O. (a) 0.0 equiv, (b) 0.31 equiv, (c) 0.68 equiv, and (d) 1.80 equiv of CB[7].




**Figure S14.** <sup>1</sup>H NMR chemical shift titration of prilocaine (1.27 mmol dm<sup>-3</sup>) with CB[7] in D<sub>2</sub>O. (●) H $\alpha$ .




**Figure S15.**  $^1\text{H}$  NMR spectra of procainamide ( $1.10 \text{ mmol dm}^{-3}$ ) with (a) 0.0 equiv, (b) 0.39 equiv, (c) 0.72 equiv, and (d) 1.88 equiv of CB[7] in  $\text{D}_2\text{O}$ .




**Figure S16.** <sup>1</sup>H NMR chemical shift titration of procainamide (1.01 mM) with CB[7] in D<sub>2</sub>O. (●) H $\beta'$ , (○) H $\alpha'$ , and (▼) H<sub>2</sub>.



**Figure S17.** <sup>1</sup>H NMR spectra of procainamide (1.01 mmol dm<sup>-3</sup>) with (a) 0.0 equiv, (b) 0.39 equiv, (c) 0.79 equiv, and (d) 1.53 equiv of CB[7] in D<sub>2</sub>O in the presence of 0.10 mol dm<sup>-3</sup> DCl.



**Figure S18.** <sup>1</sup>H NMR chemical shift titration of procainamide (1.01 mM) with CB[7] in D<sub>2</sub>O containing 0.10 mol dm<sup>-3</sup> DCl. (●) H<sub>2</sub>, (○) H<sub>3</sub>, (▼) Hβ', and (▽) Hα'.



**Figure S19.** UV titration of procaine ( $50 \mu\text{mol dm}^{-3}$ ) with CB[7] in  $\text{H}_2\text{O}$ . Inset: Dependence of absorbance at 290 nm on the concentration of CB[7].

**Table S1.** Mass spectral data for the 1:1 and 2:1 CB[7] host-guest complexes with the local anaesthetic guests in water.

Guest	1:1 Host-guest complex	2:1 Host-guest complex*
procaine	700.2551 (M•CB[7]-Cl+H) <sup>2+</sup> (700.2553 for C <sub>55</sub> H <sub>64</sub> N <sub>30</sub> O <sub>16</sub> <sup>2+</sup> ) 711.2382 (M•CB[7]-Cl+Na) <sup>2+</sup> (711.2465 for C <sub>55</sub> H <sub>63</sub> N <sub>30</sub> NaO <sub>16</sub> <sup>2+</sup> )	1292.4687 (M•2CB[7]-Cl+Na) <sup>2+</sup> (1292.4180 for C <sub>97</sub> H <sub>105</sub> N <sub>58</sub> NaO <sub>30</sub> <sup>2+</sup> )
tetracaine	714.2717 (M•CB[7]-Cl+H) <sup>2+</sup> (714.2709 for C <sub>57</sub> H <sub>68</sub> N <sub>30</sub> O <sub>16</sub> <sup>2+</sup> ) 725.2762 (M•CB[7]-Cl+Na) <sup>2+</sup> (725.2642 for C <sub>57</sub> H <sub>67</sub> N <sub>30</sub> NaO <sub>16</sub> <sup>2+</sup> )	1295.4767 (M•2CB[7]-Cl+H) <sup>2+</sup> (1295.4427 for C <sub>99</sub> H <sub>110</sub> N <sub>58</sub> O <sub>30</sub> <sup>2+</sup> )
procainamide	699.7661 (M•CB[7]-Cl+H) <sup>2+</sup> (699.7632 for C <sub>55</sub> H <sub>65</sub> N <sub>31</sub> O <sub>15</sub> <sup>2+</sup> )	1291.9526 (M•2CB[7]-Cl+Na) <sup>2+</sup> (1291.7601 for C <sub>97</sub> H <sub>106</sub> N <sub>59</sub> NaO <sub>29</sub> <sup>2+</sup> )
dibucaine	753.8056 (M•CB[7]-Cl+H) <sup>2+</sup> (753.7920 for C <sub>62</sub> H <sub>73</sub> N <sub>31</sub> O <sub>16</sub> <sup>2+</sup> )	1334.9858 (M•2CB[7]-Cl+H) <sup>2+</sup> (1334.9643 for C <sub>104</sub> H <sub>115</sub> N <sub>59</sub> O <sub>30</sub> <sup>2+</sup> ) 1345.980 (M•2CB[7]-Cl+Na) <sup>2+</sup> (1345.9553 for C <sub>104</sub> H <sub>114</sub> N <sub>59</sub> NaO <sub>30</sub> <sup>2+</sup> )
prilocaine	703.2593 (M•CB[7]-Cl+Na) <sup>2+</sup> (703.2488 for C <sub>55</sub> H <sub>63</sub> N <sub>30</sub> NaO <sub>15</sub> <sup>2+</sup> ) 1383.5430 (M•CB[7]-Cl) <sup>+</sup> (1383.5084 for C <sub>55</sub> H <sub>63</sub> N <sub>30</sub> O <sub>15</sub> <sup>+</sup> )	1284.4416 (M•2CB[7]-Cl+Na) <sup>2+</sup> (1284.4206 for C <sub>104</sub> H <sub>115</sub> N <sub>59</sub> NaO <sub>30</sub> <sup>2+</sup> )

\*The peaks for the 2:1 host-guest complexes are ~1-2% the intensity of the peaks for the 1:1 host-guest complexes.